Glioblastoma multiforme natural history

Revision as of 18:03, 18 January 2012 by Varun Kumar (talk | contribs) (Created page with "{{Glioblastoma multiforme}} {{CMG}} ==Prognosis== The median survival time from the time of diagnosis without any treatment is 3 months. Increasing age (> 60 years of age) ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Glioblastoma multiforme Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glioblastoma multiforme from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glioblastoma multiforme natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glioblastoma multiforme natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glioblastoma multiforme natural history

CDC on Glioblastoma multiforme natural history

Glioblastoma multiforme natural history in the news

Blogs on Glioblastoma multiforme natural history

Directions to Hospitals Treating Glioblastoma multiforme

Risk calculators and risk factors for Glioblastoma multiforme natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Prognosis

The median survival time from the time of diagnosis without any treatment is 3 months. Increasing age (> 60 years of age) carries a worse prognostic risk. Death is usually due to cerebral edema or increased intracranial pressure.

With standard treatment (radiotherapy, chemotherapy (such as temozolomide), and surgery), the median survival is approximately 14 months.[1] Less than 10% of these patients survive past 5 years.

A study published in 2007 reported the 2-year survival at 27.3%, 3-year survival 16.7% and 4 year survival 12.9%.[2]

References

  1. Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes A, Marosi C, Bogdahn U, Curschmann J, Janzer R, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Cairncross J, Eisenhauer E, Mirimanoff R (2005). "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma". N Engl J Med. 352 (10): 987–96. PMID 15758009.
  2. R. Mirimanoff , W. Mason , M. Van den Bent , R. Kortmann , M. Taphoorn , A. Brandes , S. Villa , G. Cairncrosss , T. Gorlia , R. Stupp International Journal of Radiation Oncology * Biology * Physics- November 2007 1 (Vol. 69, Issue 3, Page S2, DOI: 10.1016/j.ijrobp.2007.07.004) [1]


Template:WikiDoc Sources